Vaccine Development Builds on COVID-19 Breakthroughs
PharmExec
MARCH 10, 2023
New candidates are targeting cancer, infectious diseases, and RSV.
vaccine-development-builds-on-covid-19-breakthroughs 
98 
Vaccine Development Builds on COVID-19 Breakthroughs
PharmaTech
MARCH 2, 2023
Advances in vaccine development are creating partnerships and stimulating clinical trials to develop new mRNA applications.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
mRNA researchers awarded 2023 Nobel Prize
European Pharmaceutical Review
OCTOBER 2, 2023
The Nobel Assembly has awarded Hungarian biochemist Katalin Karikó and US immunologist Drew Weissman the Nobel Prize in Physiology or Medicine 2023 for their breakthrough findings in RNA vaccine development. The discovery was critical for developing effective mRNA vaccines during the COVID-19 pandemic.
Preventing the next pandemic: Supporting early-stage R&D
pharmaphorum
JULY 7, 2022
In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. Building blocks.
Funding boost for CPI’s RNA vaccine innovation centre
European Pharmaceutical Review
OCTOBER 10, 2022
million to support its work in development, scale-up and manufacture of RNA therapies and finance the training centre already established at the site, which aims to upskill the future RNA workforce. Globally, the RNA-based therapeutics and vaccines market is predicted to be valued at $2.48 billion in 2028.
Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. We have been very impressed by their vision and the relevance of their platform.”.
Industry Briefs April 2023
PM360
APRIL 7, 2023
Grifols and Selagine Tackle Dry Eyes The two eyecare leaders have entered a research, development, and sublicense agreement to develop and commercialize immunoglobulin eye drops for dry eye disease. Selagine, Inc. , Selagine, Inc. , The integrated platform ensures clients will have a clear pathway from science to value.
Let's personalize your content